Platelet in Medical Technology
Navigation Links
Platelet in Medical Technology
... and was Well Tolerated When Given With Standard platelet Therapy
KENILWORTH, N.J., March 12 ... thrombin-receptor agonist peptide (TRAP)-induced platelet aggregation inhibition, a secondary endpoint. Thrombin is the most potent platelet activator, which leads ...
... First and Only Approved platelet Producer in Europe Represents New Treatment ... Nplate, the first and only approved platelet producer in Europe, has been granted marketing ... 2008. Nplate works by raising and sustaining platelet counts, representing a novel approach for the ...
... at Sinai Hospital of Baltimore, indicate that platelet aggregation or "stickiness" may be the single ... yet the pivotal event that kills the patient - platelet aggregation isn't being assessed in any way," ... never have a cardiac event because they had low platelet aggregation. Along with his team at Sinai, ...
... monitor complete blood count (including platelet count), at least prior to each dose of DOXIL ... sarcoma, hematologic toxicity (based on platelet count or absolute neutrophil count) ... hematologic toxicity (based on platelet count, absolute neutrophil count, hemoglobin ...
... agents through immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable platelet inhibition in the chronic setting. Additionally, ... and demonstrated predictable, dose-dependent platelet inhibition. INNOVATE-PCI is designed to ...
... "These data show Nplate increased platelet counts in most patients for most of the time, and ... are at risk of serious bleeding events if their platelet counts drop to less than 30,000 per ... 74 percent of patients (160/215) achieved a platelet response defined as ...
... oral treatment for chronic ITP, a low-dose platelet transfusion strategy for patients with hypoproliferative thrombocytopenia, and a new therapeutic platelet transfusion approach following high-dose ... to minimize bleeding episodes in patients with platelet disorders," said press conference moderator ...
... more likely than those on placebo to maintain platelet counts between 50,000 to 400,000/microliters ... should not be used in an attempt to normalize platelet counts. Chronic ITP is a disorder marked by increased platelet destruction ...
... said Craig Conway, executive director of the platelet Disorder Support Association. "The approval of ... Shift in Approach "Preventing platelet destruction has always been the primary means of ... said James Bussel, M.D., director of the platelet Disorders Center, Children's Cancer and Blood ...
... PRT060128 Provides Reversible, High-level platelet Inhibition with Immediate Onset of ... a seamless transition to predictable, reversible platelet inhibition in the chronic setting. "Of the ... after the previous day's dose of clopidogrel. platelet aggregation was determined by ADP ...
... of previous studies that showed higher levels of platelet aggregation in insulin-treated diabetes ... undergoing PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking ... adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets ...
... inhibition of serotonin-mediated amplification of platelet aggregation was demonstrated starting at the 15 ... near-complete inhibition of serotonin-mediated platelet aggregation. These results further ... increased cardiovascular risk. Normally, when a platelet is activated by one of a number of factors, such ...
... crossover study compared the effects on platelet activation and bleeding time of DG041 alone and ... shown to offer a novel approach to inhibiting platelet aggregation where it is needed -- at the site of ... was shown to substantially inhibit EP3 mediated platelet activation that is not being addressed by current ...
... inhibition of serotonin-mediated amplification of platelet aggregation was demonstrated starting at the 1 ... increased cardiovascular risk. Normally, when a platelet is activated by one of a number of factors, such as thrombin or collagen, the platelet releases serotonin, which, based on preclinical ...
... purpura increased and maintained platelet counts at greater than or equal to ... study showed that of the patients with a baseline platelet count of less than 30,000/microliters, 73% ... results suggest that PROMACTA sustains increased platelet counts during long-term treatment.(1) This ...
... coronary intervention (PCI). "The inhibition of platelet aggregation plays a critical role in reducing the ... unique mechanism of action inhibits platelet aggregation through a different pathway from ... evaluable patient cohort was inhibition of platelet aggregation (IPA) induced by appropriate agonists ...
... INTEGRILIN(R) significantly decreased platelet aggregation in response to multiple stimuli, ... importance of a GP IIb-IIIa inhibitor in reducing platelet aggregation," said Paul Gurbel, MD, Director of ... study supports the role of inhibition of platelet aggregation in patients undergoing elective ...
... have identified the mechanism that accounts for platelet hyper-responsiveness during abnormal blood ... may be developed to prevent inappropriate platelet activation and reduce the risk of ... with abnormal cholesterol levels. Excessive platelet activation can lead to blood clot formation and ...
... significant improvements compared with baselines were also observed in platelet and spleen sizes, and nominally significant improvements were observed in ... the 45 U/kg IV dose, statistically significant improvements in hemoglobin, platelet count, and spleen volume were also demonstrated. The magnitude of changes ...
... acute coronary syndromes undergoing PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking ...
... Data Presentations at DDW PEGINTRON Results from the EPIC3 Program: platelet Counts Are Strong Predictors of Sustained Viral Response (SVR) in the ... 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative ...
... long-term clearance of HCV at 5-year follow-up. Manns, M. et al. platelet count predicts sustained viral response (SVR) in the retreatment of ... 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative ...
... the 20 patients (13CR/7PR) who were evaluable (at least a PR with normal platelet counts and bone marrow infiltration <25%) for subsequent Zevalin, 100% ... in 11 of 20 patients. Four patients received GCSF and 3 patients received platelet transfusions. Only 1 patient experience febrile neutropenia. The authors ...
... by their physician. Bleeding can occur at any site with LOVENOX(R) use. platelet drops, known as "thrombocytopenia," can occur with LOVENOX(R) use. Cases ... may perform blood tests to monitor for the occurrence of any drop in platelet count. The use of LOVENOX(R) has not been adequately studied in pregnant ...
... First and Only Approved platelet Producer in Europe Represents New Treatment ... Nplate, the first and only approved platelet producer in Europe, has been granted marketing ... 2008. Nplate works by raising and sustaining platelet counts, representing a novel approach for the ...
... at Sinai Hospital of Baltimore, indicate that platelet aggregation or "stickiness" may be the single ... yet the pivotal event that kills the patient - platelet aggregation isn't being assessed in any way," ... never have a cardiac event because they had low platelet aggregation. Along with his team at Sinai, ...
... monitor complete blood count (including platelet count), at least prior to each dose of DOXIL ... sarcoma, hematologic toxicity (based on platelet count or absolute neutrophil count) ... hematologic toxicity (based on platelet count, absolute neutrophil count, hemoglobin ...
... agents through immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable platelet inhibition in the chronic setting. Additionally, ... and demonstrated predictable, dose-dependent platelet inhibition. INNOVATE-PCI is designed to ...
... "These data show Nplate increased platelet counts in most patients for most of the time, and ... are at risk of serious bleeding events if their platelet counts drop to less than 30,000 per ... 74 percent of patients (160/215) achieved a platelet response defined as ...
... oral treatment for chronic ITP, a low-dose platelet transfusion strategy for patients with hypoproliferative thrombocytopenia, and a new therapeutic platelet transfusion approach following high-dose ... to minimize bleeding episodes in patients with platelet disorders," said press conference moderator ...
... more likely than those on placebo to maintain platelet counts between 50,000 to 400,000/microliters ... should not be used in an attempt to normalize platelet counts. Chronic ITP is a disorder marked by increased platelet destruction ...
Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union
... Phase 3 studies, demonstrating that platelet counts were raised and sustained in 83 percent of ... continued to effectively increase and sustain platelet counts. In this open label long term ... risk for serious bleeding events increases when platelet counts drop to less than 30,000 platelets ...... said Craig Conway, executive director of the platelet Disorder Support Association. "The approval of ... Shift in Approach "Preventing platelet destruction has always been the primary means of ... said James Bussel, M.D., director of the platelet Disorders Center, Children's Cancer and Blood ...
... PRT060128 Provides Reversible, High-level platelet Inhibition with Immediate Onset of ... a seamless transition to predictable, reversible platelet inhibition in the chronic setting. "Of the ... after the previous day's dose of clopidogrel. platelet aggregation was determined by ADP ...
... of previous studies that showed higher levels of platelet aggregation in insulin-treated diabetes ... undergoing PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking ... adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets ...
... inhibition of serotonin-mediated amplification of platelet aggregation was demonstrated starting at the 15 ... near-complete inhibition of serotonin-mediated platelet aggregation. These results further ... increased cardiovascular risk. Normally, when a platelet is activated by one of a number of factors, such ...
... crossover study compared the effects on platelet activation and bleeding time of DG041 alone and ... shown to offer a novel approach to inhibiting platelet aggregation where it is needed -- at the site of ... was shown to substantially inhibit EP3 mediated platelet activation that is not being addressed by current ...
Tailored Clopidogrel Dosing Improves PCI Outcomes
... "Tailoring the loading dose of clopidogrel using platelet monitoring seems to be the best way to decrease ... resistance was defined as more than 50 percent platelet activity after a standard 600-mg clopidogrel ... clopidogrel before PCI, and experienced a drop in platelet activity from 69.3 after the first loading dose ...FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
... treated patients with chronic ITP to increase platelet counts and reduce bleeding. "Our goal for ... in oral form for patients to help raise their platelet counts without having to suppress the immune ... Chronic ITP is a disorder marked by increased platelet destruction and/or ...BioVascular Inc. Closes $10.87 Million Series C Financing
... trials. BVI-007, a compound that acts to reduce platelet production without affecting platelet function, is being studied in a Phase Ib dose ... platelets to those fibrils. By blocking platelet adhesion, saratin blocks the first step in a ...... inhibition of serotonin-mediated amplification of platelet aggregation was demonstrated starting at the 1 ... increased cardiovascular risk. Normally, when a platelet is activated by one of a number of factors, such as thrombin or collagen, the platelet releases serotonin, which, based on preclinical ...
... purpura increased and maintained platelet counts at greater than or equal to ... study showed that of the patients with a baseline platelet count of less than 30,000/microliters, 73% ... results suggest that PROMACTA sustains increased platelet counts during long-term treatment.(1) This ...
... coronary intervention (PCI). "The inhibition of platelet aggregation plays a critical role in reducing the ... unique mechanism of action inhibits platelet aggregation through a different pathway from ... evaluable patient cohort was inhibition of platelet aggregation (IPA) induced by appropriate agonists ...
... INTEGRILIN(R) significantly decreased platelet aggregation in response to multiple stimuli, ... importance of a GP IIb-IIIa inhibitor in reducing platelet aggregation," said Paul Gurbel, MD, Director of ... study supports the role of inhibition of platelet aggregation in patients undergoing elective ...
Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies
... studies compare the levels of inhibition of platelet aggregation (IPA) in patients with coronary ... undergoing PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking ... adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets ...... have identified the mechanism that accounts for platelet hyper-responsiveness during abnormal blood ... may be developed to prevent inappropriate platelet activation and reduce the risk of ... with abnormal cholesterol levels. Excessive platelet activation can lead to blood clot formation and ...
... significant improvements compared with baselines were also observed in platelet and spleen sizes, and nominally significant improvements were observed in ... the 45 U/kg IV dose, statistically significant improvements in hemoglobin, platelet count, and spleen volume were also demonstrated. The magnitude of changes ...
Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled
... ) Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet ... industry-leading and widely accessible diagnostic tests for rapid platelet function assessment. Accumetrics' VerifyNow System is the first rapid ...New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel
... acute coronary syndromes undergoing PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking ...Schering-Plough Announces Results of the Early ACS Trial
... heparin should be stopped immediately; because INTEGRILIN inhibits platelet aggregation, caution should be employed when it is used with other drugs ... should be exercised when administering INTEGRILIN to patients with a platelet count <100,000/mm3. Bleeding is the most common complication ...American Academy Of Orthopaedic Surgeons 2009 Annual Meeting 'Highlights and Hot Topics'
... surfacing. Growth factor combinations such as bone morphogenetic protein, platelet rich plasma, and platelet derived growth factor and other potential therapeutic agents are now being ...... acute coronary syndromes undergoing PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking ...
ViaViente Demonstrates Cardiovascular Benefits in New Human Trial
... natural food product. It correlates the consumption of ViaViente to platelet inhibition -- a marker of CVD. Why is cardiovascular health so ... the production of thromboxane can help reduce vasoconstriction and platelet stickiness. Experts agree that there is a well established relationship ...FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
... Company, Limited. About Trilogy ACS The study, TRILOGY ACS (TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute ... coronary syndromes who are managed with PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking the P2Y12 adenosine ...Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial
... such as clopidogrel (Plavix(R)). These patients have a high degree of platelet reactivity and, as a result, are at greater risk of a major adverse ... industry-leading and widely accessible diagnostic tests for rapid platelet function assessment. VerifyNow is the first simple and rapid system for ...Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
... may occur; frequently monitor complete blood count (including platelet count), at least prior to each dose of DOXIL -- In patients with multiple myeloma, hematologic toxicity (based on platelet count, absolute neutrophil count, hemoglobin level, or ...... Data Presentations at DDW PEGINTRON Results from the EPIC3 Program: platelet Counts Are Strong Predictors of Sustained Viral Response (SVR) in the ... 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative ...
... long-term clearance of HCV at 5-year follow-up. Manns, M. et al. platelet count predicts sustained viral response (SVR) in the retreatment of ... 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative ...
TRITON-TIMI 38 Stent Analysis Favors Prasugrel
... from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing platelet Inhibition with Prasugrel (TRITON-TIMI 38) reveals that the ... of the "Trial to Assess Improvement in Therapeutic Outcomes by Optimizing platelet Inhibition with Prasugrel" (TRITON-TIMI 38) stent substudy on Saturday, ...Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
... With A VerifyNow Assay-Impact On Thrombosis And Safety) to establish platelet function testing with VerifyNow as the standard of care. The Executive ... of the steady progress we've made focusing on surgical procedures where platelet function testing has immediate clinical relevance and gives us an ...... the 20 patients (13CR/7PR) who were evaluable (at least a PR with normal platelet counts and bone marrow infiltration <25%) for subsequent Zevalin, 100% ... in 11 of 20 patients. Four patients received GCSF and 3 patients received platelet transfusions. Only 1 patient experience febrile neutropenia. The authors ...
... by their physician. Bleeding can occur at any site with LOVENOX(R) use. platelet drops, known as "thrombocytopenia," can occur with LOVENOX(R) use. Cases ... may perform blood tests to monitor for the occurrence of any drop in platelet count. The use of LOVENOX(R) has not been adequately studied in pregnant ...
Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting
... may occur; frequently monitor complete blood count (including platelet count), at least prior to each dose of DOXIL -- In patients with multiple myeloma, hematologic toxicity (based on platelet count, absolute neutrophil count, hemoglobin level, or neutropenia ...Other ContentsbingebingeprostaticprostaticprostaticprostaticbenignbenignbenignbenignbenignbenignbioterrorismbioterrorismbioterrorismbioterrorismbioterrorismbinocularOther TagsbuybuybulkNoseNoseNoseNosetackletackletackleRNAiRNAiurgeurgeurgeurgeurgeurgejunkOther Tagsadminister 2administer 3administer 4administer 5administer 6subtype 2incidence 2incidence 3incidence 4incidence 5incidence 6incidence 7incidence 8incidence 9
(Date:11/4/2009)..., United States Using Less Water Today , The...5 years ago, despite a 30 percent population incre... to alternative cooling methods at power plants an...the latest USGS water use report, nearly half of a... thermoelectric power plants. Irrigation accounts ...
(Date:11/4/2009)...out, hold the power to help militaries and munitio...toxic waste on test sites. , Compounds known as ...n World War II and have been used in military muni...e often used to propel tank shells and act like a ...ased knowledge of their environmentally harmful ef...
(Date:11/4/2009)...wswire/ -- Spectros, developer and manufacturer of...ich shed light on life-threatening diseases, annou...on deals for both its T-Stat® VLS Tissue Oxim...tralia, New Zealand, The Netherlands, Belgium, Lu..., Portugal, Poland, Greece, Turkey, and Russia. T...
Breaking Biology News(10 mins):USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7Genomic research will enable greener cleanup of military explosive test sites 2Spectros Signs New International Distribution Deals 2Scripps Research scientists observe human neurodegenerative disorder in fruit flies 8991 1Scripps Research scientists observe human neurodegenerative disorder in fruit flies 8991 2Scripps Research scientists observe human neurodegenerative disorder in fruit flies 8991 3Quantros Establishes IT Consulting Services Business Unit 49947 1Quantros Establishes IT Consulting Services Business Unit 49947 2Quantros Establishes IT Consulting Services Business Unit 49947 3Sentillion and Healthland Create New Efficiencies for Community Hospitals 49942 1Sentillion and Healthland Create New Efficiencies for Community Hospitals 49942 2Sentillion and Healthland Create New Efficiencies for Community Hospitals 49942 3(Date:11/5/2009)...ELES, Nov. 5 Justin Timberlake; Sa...Post were honored by the Cedars-Sinai Board of Gov... 4, 2009 at the Hyatt Regency Century Plaza in Los...us, benefitted the Cedar-Sinai Board of Governors ...n for the cause. ,, Justin Timberlake was ho...
(Date:11/5/2009)...as Important Implications for Genetic Testing and ...v. 5 Results of a lon...ent issue of Circulation play an important role in...g disease, according to the senior author, Micha...t at Mayo Clinic, Dr. Ackerman directs Mayo,s Long...
(Date:11/5/2009)...TE, N.C., Nov. 5 Southeast Anesthe...e at The Healthcare Leaders, Summit in Chile, Braz... ongoing, multi-year, continuing education event s...cal Devices & Diagnostic Group of the Johnson ...althcare quality and safety to Latin America to di...
(Date:11/5/2009)... Nov. 5 Kimberly-Clark C...ation of the waiting period under the Hart-Scott-R...ts previously announced planned acquisition of I-F...rk initiated a cash tender offer on October 20, 20...mmon stock. The tender offer will expire at midni...
(Date:11/5/2009)...URG, Ill., Nov. 5 Since...tive for the 2009 H1N1 influenza virus, pet owners...earn more: Can my pet get sick? What would the sym...w is it treated? ,, The American Veterinary Med...ct with experts and agencies across the country to...
Breaking Medicine News(10 mins):Health News:2009 Cedars-Sinai Board of Governors Gala Sponsored by Lexus Raises Over $2.6 Million 2Health News:Research Findings Key for Understanding, Interpreting Genetic Testing for Long QT Syndrome 2Health News:Research Findings Key for Understanding, Interpreting Genetic Testing for Long QT Syndrome 3Health News:Kimberly-Clark Corporation Announces Regulatory Clearance for Its Planned Acquisition of I-Flow Corporation 2Health News:Kimberly-Clark Corporation Announces Regulatory Clearance for Its Planned Acquisition of I-Flow Corporation 3Health News:Kimberly-Clark Corporation Announces Regulatory Clearance for Its Planned Acquisition of I-Flow Corporation 4[1] 2009 Cedars-Sinai Board of Governors Gala Sponsored by Lexus Raises Over $2.6 Million[1] Research Findings Key for Understanding, Interpreting Genetic Testing for Long QT Syndrome[0] Southeast Anesthesiology Consultant's CEO Speaks in Latin America[1] Kimberly-Clark Corporation Announces Regulatory Clearance for Its Planned Acquisition of I-Flow Corporation[1] AVMA Updates H1N1 Flu Resources for Pet Owners, Veterinarians
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |